汇聚学术药物研发界。
Bringing together the academic drug discovery community.
机构信息
1] ADDC President. She is also the Director of the Brain Science Institute Neuro Translational Drug Discovery Program, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA. [2].
出版信息
Nat Rev Drug Discov. 2013 Nov;12(11):811-2. doi: 10.1038/nrd4155.
Abstract
The newly formed Academic Drug Discovery Consortium (ADDC) aims to support the growing numbers of university centres engaged in drug discovery that have emerged in response to recent changes in the drug discovery ecosystem.
摘要
新成立的学术药物发现联盟（ADDC）旨在支持越来越多的参与药物发现的大学中心，这些中心是为了应对药物发现生态系统的最新变化而出现的。
相似文献
1
Bringing together the academic drug discovery community.
Nat Rev Drug Discov. 2013 Nov;12(11):811-2. doi: 10.1038/nrd4155.
2
Are academic drug discovery efforts receiving more recognition with declining industry efficiency?
Expert Opin Drug Discov. 2019 Jul;14(7):605-607. doi: 10.1080/17460441.2019.1596080. Epub 2019 Mar 26.
3
Partners in discovery.
Nature. 2018 Mar 22;555(7697):S60. doi: 10.1038/d41586-018-02897-z.
4
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.
Clin Transl Sci. 2018 Nov;11(6):597-606. doi: 10.1111/cts.12577. Epub 2018 Jul 30.
5
Drug discovery: new models for industry-academic partnerships.
Drug Discov Today. 2009 Jan;14(1-2):95-101. doi: 10.1016/j.drudis.2008.10.003. Epub 2008 Nov 21.
6
Academic drug discovery: current status and prospects.
Expert Opin Drug Discov. 2015;10(9):937-44. doi: 10.1517/17460441.2015.1059816. Epub 2015 Jun 19.
7
Pharmaceutical pipeline.
Minn Med. 2011 Oct;94(10):16-8.
8
Opening the lead generation toolbox.
Nat Rev Drug Discov. 2014 Jan;13(1):3-4. doi: 10.1038/nrd4202.
9
How academic labs can approach the drug discovery process as a way to synergize with big pharma.
Trends Microbiol. 2013 Jun;21(6):261-4. doi: 10.1016/j.tim.2013.03.006.
10
Vertical disintegration: a strategy for pharmaceutical businesses in 2009?
Nat Rev Drug Discov. 2009 Jun;8(6):435. doi: 10.1038/nrd2914.
引用本文的文献
1
Fragment-Based Screening Identifies New Quinazolinone-Based Inositol Hexakisphosphate Kinase (IP6K) Inhibitors.
ACS Med Chem Lett. 2023 Nov 28;14(12):1760-1766. doi: 10.1021/acsmedchemlett.3c00409. eCollection 2023 Dec 14.
2
Merging cultures and disciplines to create a drug discovery ecosystem at Virginia commonwealth university: Medicinal chemistry, structural biology, molecular and behavioral pharmacology and computational chemistry.
SLAS Discov. 2023 Sep;28(6):255-269. doi: 10.1016/j.slasd.2023.02.006. Epub 2023 Feb 28.
3
dockECR: Open consensus docking and ranking protocol for virtual screening of small molecules.
J Mol Graph Model. 2021 Dec;109:108023. doi: 10.1016/j.jmgm.2021.108023. Epub 2021 Sep 15.
4
The Use of Informer Sets in Screening: Perspectives on an Efficient Strategy to Identify New Probes.
SLAS Discov. 2021 Aug;26(7):855-861. doi: 10.1177/24725552211019410. Epub 2021 Jun 16.
5
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.
Comput Struct Biotechnol J. 2021;19:2537-2548. doi: 10.1016/j.csbj.2021.04.059. Epub 2021 Apr 26.
6
Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery.
Front Pharmacol. 2020 Jun 30;11:770. doi: 10.3389/fphar.2020.00770. eCollection 2020.
7
A Curiously Linear Path to Academic Drug Discovery.
ACS Med Chem Lett. 2020 Mar 12;11(3):217-220. doi: 10.1021/acsmedchemlett.9b00459.
8
Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.
Trends Mol Med. 2020 Feb;26(2):150-169. doi: 10.1016/j.molmed.2019.10.001. Epub 2019 Nov 7.
9
Challenges with risk mitigation in academic drug discovery: finding the best solution.
Expert Opin Drug Discov. 2019 Feb;14(2):95-100. doi: 10.1080/17460441.2019.1553952. Epub 2018 Dec 4.
10
Early Probe and Drug Discovery in Academia: A Minireview.
High Throughput. 2018 Feb 9;7(1):4. doi: 10.3390/ht7010004.
本文引用的文献
1
Drug development: Raise standards for preclinical cancer research.
Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a.
2
Trial watch: Phase II failures: 2008-2010.
Nat Rev Drug Discov. 2011 May;10(5):328-9. doi: 10.1038/nrd3439.
3
Trial watch: phase III and submission failures: 2007-2010.
Nat Rev Drug Discov. 2011 Feb;10(2):87. doi: 10.1038/nrd3375.
4
How to improve R&D productivity: the pharmaceutical industry's grand challenge.
Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078. Epub 2010 Feb 19.
Zotero 插件